The biotech market showed strong signs of recovery in early 2024, with the XBI index up 14% year-to-date. Unlike the late 2023 uptick driven by macro factors, this surge is fueled by positive, company-specific clinical data, suggesting a more fundamental and sustainable rally.
Private Investment in Public Equity (PIPE) deals, specifically the 'wall-crossed' variant, have become the dominant financing tool for development-stage biotechs, with over 30 deals raising $4 billion in early 2024. These deals involve sharing material non-public information, like upcoming clinical trial results, with a select group of investors.
Intense investor appetite for obesity treatments remains a powerful market force, exemplified by Viking Therapeutics' valuation soaring from $700 million to over $9 billion in a year on promising data. This enthusiasm is also creating a halo effect, with many obesity drug candidates now being explored for related conditions like the liver disease MASH.
The popularity of 'wall-crossed' PIPEs follows previous trends like SPACs and crossover rounds, where hedge funds seek an edge by gaining early access. This has sparked a debate, with some large institutional investors refusing to participate due to compliance concerns, while others feel pressured to join to remain competitive.
Keep pulling the thread on Viking Therapeutics.